What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CMT-133 in healthy adult participants after single or multiple doses. It is a randomized, double-blind, placebo-controlled, SAD and MAD study, which will be conducted in Parts A and B, respectively. CMT-133 will be administered via SC injection. Placebo will consist of normal saline administered via the same route (SC) and in a manner indistinguishable from active treatment.”In the company’s words, NCT07926737 on ClinicalTrials.gov
Coming up1
- May 2028Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07926737
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | May 2028 | CMT-133 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026